Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning how a drug moves into, through, and out of the body — in both children and adults. That’s according to data from the Phase 3 QUANTI Pediatric study (NCT05915026), which evaluated the safety and pharmacological properties […]
The post New MRI contrast agent shows similar safety in children, adults appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com